Literatuur
- Grothey A et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018. 378(13): 1177-88
- Simkens LH et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015. 385(9980): 1843-52
- Goey KKH et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017. 28(9): 2128-34
- Hegewisch-Becker S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015. 16(13): 1355-69
- Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008. 371(9617): 1007-16
- Loupakis F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371(17): 1609-18
- Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015. 26(4): 702-8
- Xu RH et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. The Lancet Oncology. 2018 19(5): 660-71
- Schmiegel W. et al. Capecitabine / irinotecan or capecitabine / oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013. 24(6): 1580-7
- Yan TD et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36): 6237-42
- Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia. Ann Surg Oncol. 2010. 17(6): 1710-2; author reply 3-4
- Bahadoer RR et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021. 22(1): 29-42
- Dijkstra EA et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023 Oct 1; 278(4): 766-772
- Prager GW et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023. 388: 1657-67
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over Colorectaal carcinoom.
Richtlijnen
Ga naar de richtlijn Colorectaal carcinoom in de FMS richtlijnendatabase.